Xlab, Center for Healthy Aging, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Department of Dermatology, Bispebjerg-Frederiksberg University Hospital, Copenhagen, Denmark.
Endocrinol Diabetes Metab. 2024 Nov;7(6):e70002. doi: 10.1002/edm2.70002.
Tumour necrosis factor (TNF)-α is a proinflammatory marker and has been shown to affect mitochondrial function in different tissues. We investigated the effect on adipose tissue (AT) inflammation and mitochondrial respiration in patients with hidradenitis suppurativa (HS) after 12 weeks of treatment with adalimumab, a TNF-α inhibitor.
We sampled blood and an AT biopsy from 13 patients with HS and 10 control subjects after an overnight fast. The patients were retested after at least 12 weeks of treatment with adalimumab (40 mg/week). We measured macrophage content and mitochondrial respiration in the AT and interleukin (IL)-1β, IL-6, IL-10, high-sensitivity C-reactive protein (hsCRP), interferon-γ, TNF-α, adiponectin and leptin in plasma. Clinical scores and Dermatology Quality of Life Index (DLQI) were assessed.
We found a higher anti-inflammatory macrophage content (CD206) in the patient group compared with the control group, but no differences between before and after the intervention. No difference in mitochondrial respiration was observed. We observed higher plasma IL-6 and hsCRP concentrations in patients with HS compared to controls, with no differences before and after the intervention. The difference between controls and HS patients was abolished after the intervention. HS patients improved their DLQI after the intervention with no change in clinical scores.
Treatment with adalimumab in patients with HS does not alter AT inflammation or mitochondrial respiratory capacity; however, we did see a higher content of anti-inflammatory macrophages in the patient group compared with the control group.
肿瘤坏死因子（TNF）-α是一种促炎标志物，已被证明会影响不同组织中的线粒体功能。我们研究了在接受 TNF-α抑制剂阿达木单抗治疗 12 周后，对患有化脓性汗腺炎（HS）患者的脂肪组织（AT）炎症和线粒体呼吸的影响。
我们在禁食过夜后，从 13 名 HS 患者和 10 名对照者中抽取血液和 AT 活检。在至少接受 12 周阿达木单抗（40mg/周）治疗后，我们对患者进行了再次检测。我们测量了 AT 中的巨噬细胞含量和线粒体呼吸，以及血浆中的白细胞介素（IL）-1β、IL-6、IL-10、高敏 C 反应蛋白（hsCRP）、干扰素-γ、TNF-α、脂联素和瘦素。评估了临床评分和皮肤病生活质量指数（DLQI）。
与对照组相比，我们发现患者组的抗炎性巨噬细胞含量（CD206）更高，但干预前后没有差异。未观察到线粒体呼吸的差异。与对照组相比，HS 患者的血浆 IL-6 和 hsCRP 浓度更高，干预前后无差异。干预后，这种 HS 患者与对照组之间的差异被消除。HS 患者在干预后改善了 DLQI，临床评分无变化。
在 HS 患者中使用阿达木单抗治疗不会改变 AT 炎症或线粒体呼吸能力；然而，与对照组相比，我们确实发现患者组的抗炎性巨噬细胞含量更高。
